How UPMC Hillman and Krystal Biotech will be working together on a new cancer treatment


It's the Pittsburgh-based biotech firm's first foray into oncology.

Previous Advent Therapeutics lands $3M NIH grant to advance therapy to benefit premature infants
Next Carmell Therapeutics plans to acquire Arizona biotech firm for $65M